NDA 21919, held by Amylin. Exenatide Synthetic.
As of Nov 14, 2026, NDA 21919 (Byetta), held by Amylin, was first approved by FDA on Oct 30, 2009, with 0 approved supplements and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Oct 30, 2009 | Original applicationTYPE 6 · Standard review | Approved |
| Byetta300UGM/1.2ML (250UGM/ML) · injectable; subcutaneous | Exenatide Synthetic | Rx |
| Byetta600UGM/2.4ML (250UGM/ML) · injectable; subcutaneous | Exenatide Synthetic | Rx |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters